Struggles and Opportunities for Tobacco Giant Altria.

Aug.10.2022
Struggles and Opportunities for Tobacco Giant Altria.
Altria, a tobacco giant, has suffered setbacks with investments in Juul Labs and IQOS, causing a decline in their stock value.

A tobacco giant has just gone through a series of unfortunate events.


Altria finds itself in a position where its traditional cigarette business has been more successful than its newer tobacco products.


Tobacco company Altria fell short of analysts' revenue predictions for the second quarter, but exceeded profit expectations. Its investment in e-cigarette manufacturer Juul Labs was dealt a major blow by the US Food and Drug Administration, which ordered the removal of its products from store shelves.


Photo credit: GETTY IMAGES


Meanwhile, the US International Trade Commission has ruled that the import of IQOS heated tobacco devices by Philip Morris International into the country is prohibited. These devices are sold under Altria's Marlboro heated tobacco brand, resulting in a setback for Altria's harm reduction product development.


This is reflected in its stock price, which has dropped by one-fifth in the past three months. These stocks rose by 20% in June, but have fallen by nearly 7% overall this year. This has left investors questioning whether it is worthwhile to purchase Altria's stocks.


With traditional smoking rates in long-term decline, Altria is now the only major tobacco company on the market without an electronic cigarette. Let's take a look at whether adding this tobacco stock to your investment portfolio would result in losses.


Negatively impacted by the market.


Inflation also comes at a cost. While Altria's own expenses are rising as a result, its customers are also having to deal with skyrocketing food and energy costs, which reduces their limited disposable income and leads them to prioritize their investments.


In the first quarter, revenues decreased by 5.7% to $6.5 billion, although this figure includes the impact of Altria's sale of its wine business in October last year. After deducting consumption tax, revenues decreased by 4.3% to $5.4 billion.


However, adjusted profits increased by nearly 3%, to $1.26 per share, as Altria repurchased over 21 million shares of stock in the first six months of this year. Although net profits declined, this was largely due to Altria's investments in Juul, Anheuser-Busch InBev, and cannabis producer Cronos.


Despite performing well, the brewery had to completely write off its investments in Russia - the rise in foreign exchange rates temporarily lowered the fair value of these investments below their book value, resulting in non-cash impairment charges. Cronos also weighed on performance, causing a $120 million loss in equity investments for the quarter.


However, the true heavy blow was to Juul, as Altria's $13.4 billion investment in the company has now decreased in value by 35%. It has now been valued at $450 million due to the decreased likelihood of the FDA revoking its decision on Juul products (the agency did indeed pause the ban to review its decision). If the FDA upholds its ban, Juul is expected to declare bankruptcy.


Rising from the ashes.


This appears to be a gloomy landscape, but Altria also has many things to do.


The company can once again invest in its electronic cigarette business, as its investment in Juul prevented it from doing so unless the transaction value decreased by 90% or more. With experience in such products through its previously shelved MarkTen brand, it can relaunch these products or even acquire existing ones.


Altria has also invested in other smokeless tobacco options, including nasal snuff and nicotine pouches. It owns the Copenhagen and Skoal brands of nasal snuff, as well as the On! brand of nicotine pouches that was introduced a few years ago.


Tobacco products that are consumed orally make up nearly 47% of the market, with the 200-year-old Copenhagen brand holding a leading position with a 27.2% market share. The On! brand has grown to almost 5% of the market. Altria's Marlboro brand has been the market leader for the past 45 years, continuing to hold close to half of the traditional cigarette market.


Development opportunities


Altria is performing well financially, with its stock being very affordable, trading at only eight times next year's earnings. The stock is priced at around $44 per share, a departure from 2015 and the market crash earlier in the pandemic.


Altria's stock is an attractive buy with its rich 8.1% dividend, which has increased annually for over 50 years and earned it the title of dividend king.


Statement:


This article is compiled from third-party information and is solely intended for industry professionals to share and learn from.


This article does not represent the views of 2FIRSTS, and 2FIRSTS cannot confirm the authenticity and accuracy of its contents. The translation of this article is only intended for communication and research within the industry.


Due to limitations in translation abilities, the translated article may not accurately reflect the original text. Please refer to the original text for accuracy.


2FIRSTS aligns completely with the Chinese government's domestic, Hong Kong/Macau/Taiwan-related, and international expressions and positions.


The copyright of the compiled information belongs to the original media and author. If there is any infringement, please contact us for deletion.



Disclaimer

This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.

Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.

The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.

This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.

 

Copyright Notice

This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.

No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.

For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.

 

AI-Assisted Translation and Editing Notice

Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.

Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.

Product | OXVA Introduces XLIM PRO 4 With Liquid-Level Anti-Burn Technology and Dedicated Pods
Product | OXVA Introduces XLIM PRO 4 With Liquid-Level Anti-Burn Technology and Dedicated Pods
Vaping brand OXVA introduced the XLIM PRO 4 refillable pod system in October 2026, featuring Anti-Burn Tech (ABT) based on smart e-liquid-level detection. The system can issue refill alerts and stop power output when e-liquid levels become too low. ABT requires the XLIM PRO 4 device and a dedicated XLIM ABT cartridge. Standard XLIM pods remain compatible but do not support ABT protection. OXVA previously introduced temperature-based anti-burn technology in the XLIM Pro 2 DNA, developed with Evolv. The new device features a 1,800mAh battery, 5–30W output and a 0.98-inch HD color screen. OXVA's official store lists the device at $37.90 and dedicated ABT replacement cartridges at $12.99. Independent testing confirmed the low-liquid protection response but recorded varying cartridge lifespans.
product
Oct.30
On-Site Report | CTP Details PMTA Backlog, 180-Day Review Goal and sPMTA Process
On-Site Report | CTP Details PMTA Backlog, 180-Day Review Goal and sPMTA Process
FDA’s Center for Tobacco Products detailed new PMTA review data and process changes at the 2026 FDLI conference. Pending PMTAs fell from about 450,000 at the start of 2025 to 135,000 by September 2026. CTP also discussed its 180-day review goal, current sPMTA pilot, alternate-supplier planning, more than 50,300 pending SE reports, and lessons from the nicotine pouch pilot already being applied to ENDS review.
Regulations
Oct.07
Ukraine Raises Excise Stamp Fees for Tobacco, Heated Tobacco and Vape Liquids by 30.5% as Parliament Backs E-Excise Delay to 2027
Ukraine Raises Excise Stamp Fees for Tobacco, Heated Tobacco and Vape Liquids by 30.5% as Parliament Backs E-Excise Delay to 2027
Ukraine's Cabinet of Ministers adopted Resolution No. 1259 on October 15, 2026, increasing excise stamp production fees for tobacco products and e-cigarette liquids by approximately 30.5%, from UAH 0.1643 to UAH 0.2144 per stamp. Fees for alcoholic beverages rose by about 30.2%. Separately, Ukraine's parliament passed Bill No. 15532 on October 13, proposing to postpone the full implementation of electronic excise stamps and traceability for alcohol, tobacco and e-cigarette liquids from November 1, 2026, to July 1, 2027. Parliament cited additional testing, configuration and integration requirements. The bill was sent to the president for signature on October 19.
Regulations
Oct.21
US ITC Judge Finds Glas Infringed Two JUUL Vape Patents, Recommends Restrictions on Related Imports——Glas Received FDA Marketing Authorization for Four Vape Pods in May 2026; Proposed Restrictions Remain Under Commission Review
US ITC Judge Finds Glas Infringed Two JUUL Vape Patents, Recommends Restrictions on Related Imports——Glas Received FDA Marketing Authorization for Four Vape Pods in May 2026; Proposed Restrictions Remain Under Commission Review
A U.S. International Trade Commission (USITC) administrative law judge issued an initial determination on October 20, 2026, finding that certain Glas vaping devices, cartridges and components infringed 12 claims across two patents asserted by JUUL, constituting a violation of Section 337 of the Tariff Act of 1930. The judge recommended a limited exclusion order and a cease and desist order against the Glas respondents. Five months earlier, the FDA authorized four Glas e-cigarette pods, including mango, blueberry and two menthol variants. The patent investigation concerns device and cartridge structures and is separate from FDA premarket review. The proposed import restrictions have not become final, and their product-level scope remains unresolved.
company
Nov.05
U.S. Judge Stays Helix, NJOY Challenge to FDA PMTA Rule Pending New Rulemaking Court Stays Altria's Helix, NJOY Challenge to PMTA Rule as FDA Prepares New Rulemaking
U.S. Judge Stays Helix, NJOY Challenge to FDA PMTA Rule Pending New Rulemaking Court Stays Altria's Helix, NJOY Challenge to PMTA Rule as FDA Prepares New Rulemaking
A federal judge in Texas on Oct. 8 granted a joint request by the FDA and plaintiffs including Altria subsidiaries Helix Innovations and NJOY to stay litigation challenging the agency's 2021 PMTA rule. The court cited FDA's anticipated rulemaking concerning the regulation at issue. FDA announced on Sept. 28 that it intends to reassess the PMTA framework and could initiate new rulemaking to replace it. The parties must file a joint status report within 45 days and every 45 days thereafter. A motion by three Reynolds American companies to intervene remains pending.
Regulations
Oct.10
Indonesia's Influential Islamic Body MUI Urges Vape Permit Freeze, Raising Uncertainty for 200 Manufacturers
Indonesia's Influential Islamic Body MUI Urges Vape Permit Freeze, Raising Uncertainty for 200 Manufacturers
Indonesia's Ulema Council (MUI) published Fatwa No. 131/2026 on November 9, declaring electronic cigarette use, production and trade haram under Islamic religious rules. The council urged the Industry Ministry to prohibit the issuance of vape industry permits and review licensing policies, while calling on the president and parliament to enact a comprehensive ban. On November 10, the Constitutional Court heard a challenge to provisions of the 2023 Health Law seeking a prohibition on vape production, importation, distribution and use. The Health Ministry said on November 11 it was studying stronger restrictions, including a possible ban on circulation, while industry association APVI called for tighter oversight rather than a total ban. Indonesia's Industry Ministry previously estimated the sector comprises about 200 companies, Rp31 trillion ($1.7 billion) in cumulative investment and approximately 100,000 supply-chain jobs. No nationwide statutory ban has been enacted.
Regulations
Nov.12